#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


1-1	0-7	Mothers	http://maven.renci.org/NeuroBridge/neurobridge#PsychoactiveSubstanceAbuse
1-2	8-12	with	http://maven.renci.org/NeuroBridge/neurobridge#PsychoactiveSubstanceAbuse
1-3	13-22	Substance	http://maven.renci.org/NeuroBridge/neurobridge#PsychoactiveSubstanceAbuse
1-4	23-33	Addictions	http://maven.renci.org/NeuroBridge/neurobridge#PsychoactiveSubstanceAbuse
1-5	34-38	Show	_
1-6	39-46	Reduced	_
1-7	47-53	Reward	_
1-8	54-63	Responses	_
1-9	64-68	When	_
1-10	69-76	Viewing	_
1-11	77-82	Their	_
1-12	83-86	Own	_
1-13	87-93	Infant	_
1-14	94-95	’	http://maven.renci.org/NeuroBridge/neurobridge#SF36Questionnaire
1-15	96-97	s	http://maven.renci.org/NeuroBridge/neurobridge#SF36Questionnaire
1-16	98-102	Face	_
1-17	103-111	Maternal	_
1-18	112-121	addiction	_
1-19	122-133	constitutes	_
1-20	134-135	a	_
1-21	136-141	major	_
1-22	142-148	public	_
1-23	149-155	health	_
1-24	156-163	problem	_
1-25	164-173	affecting	_
1-26	174-182	children	_
1-27	183-184	,	_
1-28	185-189	with	_
1-29	190-194	high	_
1-30	195-200	rates	_
1-31	201-203	of	_
1-32	204-209	abuse	_
1-33	210-211	,	_
1-34	212-219	neglect	_
1-35	220-221	,	_
1-36	222-225	and	_
1-37	226-232	foster	_
1-38	233-237	care	_
1-39	238-247	placement	_
1-40	248-249	.	_

2-1	250-257	However	_
2-2	258-259	,	_
2-3	260-266	little	_
2-4	267-269	is	_
2-5	270-275	known	_
2-6	276-281	about	_
2-7	282-285	the	_
2-8	286-290	ways	_
2-9	291-293	in	_
2-10	294-299	which	_
2-11	300-309	substance	_
2-12	310-319	addiction	_
2-13	320-326	alters	_
2-14	327-332	brain	_
2-15	333-341	function	_
2-16	342-349	related	_
2-17	350-352	to	_
2-18	353-361	maternal	_
2-19	362-370	behavior	_
2-20	371-372	.	_

3-1	373-378	Prior	_
3-2	379-386	studies	_
3-3	387-391	have	_
3-4	392-397	shown	_
3-5	398-402	that	_
3-6	403-409	infant	_
3-7	410-414	face	_
3-8	415-419	cues	_
3-9	420-428	activate	_
3-10	429-436	similar	_
3-11	437-456	dopamine-associated	_
3-12	457-462	brain	_
3-13	463-469	reward	_
3-14	470-477	regions	_
3-15	478-480	to	_
3-16	481-491	substances	_
3-17	492-494	of	_
3-18	495-500	abuse	_
3-19	501-502	.	_

4-1	503-507	Here	_
4-2	508-509	,	_
4-3	510-512	we	_
4-4	513-519	report	_
4-5	520-522	on	_
4-6	523-524	a	_
4-7	525-535	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
4-8	536-539	MRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
4-9	540-545	study	_
4-10	546-557	documenting	_
4-11	558-562	that	_
4-12	563-570	mothers	http://maven.renci.org/NeuroBridge/neurobridge#SubjectwithoutDisorder
4-13	571-575	with	http://maven.renci.org/NeuroBridge/neurobridge#SubjectwithoutDisorder
4-14	576-586	addictions	http://maven.renci.org/NeuroBridge/neurobridge#SubjectwithoutDisorder
4-15	587-598	demonstrate	_
4-16	599-606	reduced	_
4-17	607-617	activation	_
4-18	618-620	of	_
4-19	621-627	reward	_
4-20	628-635	regions	_
4-21	636-640	when	_
4-22	641-646	shown	_
4-23	647-661	reward-related	_
4-24	662-666	cues	_
4-25	667-669	of	_
4-26	670-675	their	_
4-27	676-679	own	_
4-28	680-687	infants	_
4-29	688-689	.	_

5-1	690-700	Thirty-six	_
5-2	701-708	mothers	_
5-3	709-718	receiving	_
5-4	719-728	inpatient	_
5-5	729-738	treatment	_
5-6	739-742	for	_
5-7	743-752	substance	_
5-8	753-762	addiction	http://maven.renci.org/NeuroBridge/neurobridge#AddictionSeverityIndex
5-9	763-767	were	_
5-10	768-775	scanned	_
5-11	776-778	at	_
5-12	779-780	6	_
5-13	781-787	months	_
5-14	788-798	postpartum	_
5-15	799-800	,	_
5-16	801-806	while	_
5-17	807-814	viewing	_
5-18	815-820	happy	_
5-19	821-824	and	_
5-20	825-828	sad	_
5-21	829-833	face	_
5-22	834-840	images	_
5-23	841-843	of	_
5-24	844-849	their	_
5-25	850-853	own	_
5-26	854-860	infant	_
5-27	861-869	compared	_
5-28	870-872	to	_
5-29	873-878	those	_
5-30	879-881	of	_
5-31	882-883	a	_
5-32	884-891	matched	_
5-33	892-899	unknown	_
5-34	900-906	infant	_
5-35	907-908	.	_

6-1	909-913	When	_
6-2	914-921	viewing	_
6-3	922-927	happy	_
6-4	928-932	face	_
6-5	933-939	images	_
6-6	940-942	of	_
6-7	943-948	their	_
6-8	949-952	own	_
6-9	953-959	infant	_
6-10	960-961	,	_
6-11	962-969	mothers	http://maven.renci.org/NeuroBridge/neurobridge#SubjectwithoutDisorder
6-12	970-974	with	http://maven.renci.org/NeuroBridge/neurobridge#SubjectwithoutDisorder
6-13	975-985	addictions	http://maven.renci.org/NeuroBridge/neurobridge#SubjectwithoutDisorder
6-14	986-992	showed	_
6-15	993-994	a	_
6-16	995-1003	striking	_
6-17	1004-1011	pattern	_
6-18	1012-1014	of	_
6-19	1015-1024	decreased	_
6-20	1025-1035	activation	_
6-21	1036-1038	in	_
6-22	1039-1048	dopamine-	_
6-23	1049-1052	and	_
6-24	1053-1072	oxytocin-innervated	_
6-25	1073-1078	brain	_
6-26	1079-1086	regions	_
6-27	1087-1088	,	_
6-28	1089-1098	including	_
6-29	1099-1102	the	_
6-30	1103-1115	hypothalamus	_
6-31	1116-1117	,	_
6-32	1118-1125	ventral	_
6-33	1126-1134	striatum	_
6-34	1135-1136	,	_
6-35	1137-1140	and	_
6-36	1141-1153	ventromedial	_
6-37	1154-1164	prefrontal	_
6-38	1165-1179	cortex—regions	_
6-39	1180-1182	in	_
6-40	1183-1188	which	_
6-41	1189-1198	increased	_
6-42	1199-1209	activation	_
6-43	1210-1213	has	_
6-44	1214-1224	previously	_
6-45	1225-1229	been	_
6-46	1230-1238	observed	_
6-47	1239-1241	in	_
6-48	1242-1249	mothers	_
6-49	1250-1257	without	_
6-50	1258-1268	addictions	_
6-51	1269-1270	.	_

7-1	1271-1274	Our	_
7-2	1275-1282	results	_
7-3	1283-1286	are	_
7-4	1287-1290	the	_
7-5	1291-1296	first	_
7-6	1297-1299	to	_
7-7	1300-1311	demonstrate	_
7-8	1312-1316	that	_
7-9	1317-1324	mothers	http://maven.renci.org/NeuroBridge/neurobridge#SubjectwithoutDisorder
7-10	1325-1329	with	http://maven.renci.org/NeuroBridge/neurobridge#SubjectwithoutDisorder
7-11	1330-1340	addictions	http://maven.renci.org/NeuroBridge/neurobridge#SubjectwithoutDisorder
7-12	1341-1345	show	_
7-13	1346-1353	reduced	_
7-14	1354-1364	activation	_
7-15	1365-1367	in	_
7-16	1368-1371	key	_
7-17	1372-1378	reward	_
7-18	1379-1386	regions	_
7-19	1387-1389	of	_
7-20	1390-1393	the	_
7-21	1394-1399	brain	_
7-22	1400-1402	in	_
7-23	1403-1411	response	_
7-24	1412-1414	to	_
7-25	1415-1420	their	_
7-26	1421-1424	own	_
7-27	1425-1431	infant	_
7-28	1432-1433	’	_
7-29	1434-1435	s	_
7-30	1436-1440	face	_
7-31	1441-1445	cues	_
7-32	1446-1447	.	_

8-1	1448-1457	Materials	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
8-2	1458-1461	and	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
8-3	1462-1469	Methods	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
8-4	1470-1482	Participants	_
8-5	1483-1493	Thirty-six	_
8-6	1494-1504	postpartum	_
8-7	1505-1512	mothers	_
8-8	1513-1520	ranging	_
8-9	1521-1523	in	_
8-10	1524-1527	age	_
8-11	1528-1532	from	_
8-12	1533-1535	21	_
8-13	1536-1538	to	_
8-14	1539-1541	47	_
8-15	1542-1543	(	_
8-16	1544-1545	M	_
8-17	1546-1547	=	_
8-18	1548-1552	27.8	_
8-19	1553-1554	±	_
8-20	1555-1558	5.6	_
8-21	1559-1560	)	_
8-22	1561-1566	years	_
8-23	1567-1571	were	_
8-24	1572-1581	recruited	_
8-25	1582-1586	from	_
8-26	1587-1589	an	_
8-27	1590-1599	inpatient	_
8-28	1600-1609	treatment	_
8-29	1610-1619	facility1	_
8-30	1620-1623	for	_
8-31	1624-1637	substance-use	_
8-32	1638-1647	disorders	http://maven.renci.org/NeuroBridge/neurobridge#ExtrapyramidalDisease
8-33	1648-1649	.	_

9-1	1650-1653	All	_
9-2	1654-1666	participants	_
9-3	1667-1671	were	_
9-4	1672-1679	English	_
9-5	1680-1688	speaking	_
9-6	1689-1690	,	_
9-7	1691-1694	met	_
9-8	1695-1703	criteria	_
9-9	1704-1707	for	_
9-10	1708-1711	one	_
9-11	1712-1714	or	_
9-12	1715-1719	more	_
9-13	1720-1733	substance-use	_
9-14	1734-1742	disorder	_
9-15	1743-1749	within	_
9-16	1750-1753	the	_
9-17	1754-1758	past	_
9-18	1759-1763	year	_
9-19	1764-1766	as	_
9-20	1767-1775	assessed	_
9-21	1776-1778	by	_
9-22	1779-1782	the	_
9-23	1783-1787	Mini	_
9-24	1788-1801	International	_
9-25	1802-1818	Neuropsychiatric	_
9-26	1819-1828	Interview	_
9-27	1829-1832	6.0	_
9-28	1833-1834	(	_
9-29	1835-1839	MINI	_
9-30	1840-1841	)	_
9-31	1842-1843	,	_
9-32	1844-1847	and	_
9-33	1848-1856	reported	_
9-34	1857-1858	a	_
9-35	1859-1866	history	_
9-36	1867-1869	of	_
9-37	1870-1879	substance	_
9-38	1880-1883	use	_
9-39	1884-1890	during	_
9-40	1891-1894	the	_
9-41	1895-1899	most	_
9-42	1900-1906	recent	_
9-43	1907-1916	pregnancy	_
9-44	1917-1918	.	_

10-1	1919-1928	Potential	_
10-2	1929-1941	participants	_
10-3	1942-1946	were	_
10-4	1947-1955	excluded	_
10-5	1956-1958	if	_
10-6	1959-1962	any	_
10-7	1963-1965	of	_
10-8	1966-1969	the	_
10-9	1970-1979	following	_
10-10	1980-1988	criteria	_
10-11	1989-1993	were	_
10-12	1994-1997	met	_
10-13	1998-1999	:	_
10-14	2000-2001	(	_
10-15	2002-2003	a	_
10-16	2004-2005	)	_
10-17	2006-2012	severe	_
10-18	2013-2024	psychiatric	_
10-19	2025-2033	symptoms	_
10-20	2034-2043	requiring	_
10-21	2044-2053	inpatient	_
10-22	2054-2069	hospitalization	_
10-23	2070-2071	;	_
10-24	2072-2073	(	_
10-25	2074-2075	b	_
10-26	2076-2077	)	_
10-27	2078-2082	past	_
10-28	2083-2085	or	_
10-29	2086-2093	present	_
10-30	2094-2103	diagnosis	_
10-31	2104-2106	of	_
10-32	2107-2120	schizophrenia	_
10-33	2121-2123	or	_
10-34	2124-2129	other	_
10-35	2130-2139	psychotic	_
10-36	2140-2149	disorders	_
10-37	2150-2151	;	_
10-38	2152-2153	(	_
10-39	2154-2155	c	_
10-40	2156-2157	)	_
10-41	2158-2165	pending	_
10-42	2166-2171	legal	_
10-43	2172-2177	cases	_
10-44	2178-2179	(	_
10-45	2180-2184	e.g.	_
10-46	2185-2186	,	_
10-47	2187-2198	outstanding	_
10-48	2199-2205	arrest	_
10-49	2206-2214	warrants	_
10-50	2215-2217	or	_
10-51	2218-2226	parental	_
10-52	2227-2233	rights	_
10-53	2234-2242	hearings	_
10-54	2243-2244	)	_
10-55	2245-2246	;	_
10-56	2247-2248	(	_
10-57	2249-2250	d	_
10-58	2251-2252	)	_
10-59	2253-2265	insufficient	_
10-60	2266-2273	English	_
10-61	2274-2281	fluency	_
10-62	2282-2292	precluding	_
10-63	2293-2302	interview	_
10-64	2303-2314	assessments	_
10-65	2315-2316	;	_
10-66	2317-2318	(	_
10-67	2319-2320	e	_
10-68	2321-2322	)	_
10-69	2323-2340	contraindications	_
10-70	2341-2344	for	_
10-71	2345-2348	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
10-72	2349-2357	scanning	_
10-73	2358-2359	;	_
10-74	2360-2361	(	_
10-75	2362-2363	f	_
10-76	2364-2365	)	_
10-77	2366-2377	out-of-home	_
10-78	2378-2387	placement	_
10-79	2388-2390	of	_
10-80	2391-2397	infant	_
10-81	2398-2401	for	_
10-82	2402-2405	the	_
10-83	2406-2410	past	_
10-84	2411-2416	month	_
10-85	2417-2419	or	_
10-86	2420-2421	>	_
10-87	2422-2424	50	_
10-88	2425-2426	%	_
10-89	2427-2429	of	_
10-90	2430-2436	infant	_
10-91	2437-2438	’	_
10-92	2439-2440	s	_
10-93	2441-2445	life	_
10-94	2446-2447	;	_
10-95	2448-2450	or	_
10-96	2451-2452	(	_
10-97	2453-2454	g	_
10-98	2455-2456	)	_
10-99	2457-2466	premature	_
10-100	2467-2472	birth	_
10-101	2473-2475	of	_
10-102	2476-2483	infants	_
10-103	2484-2485	,	_
10-104	2486-2494	clinical	_
10-105	2495-2503	evidence	_
10-106	2504-2506	of	_
10-107	2507-2515	in-utero	_
10-108	2516-2520	drug	_
10-109	2521-2528	effects	_
10-110	2529-2530	,	_
10-111	2531-2533	or	_
10-112	2534-2539	other	_
10-113	2540-2546	infant	_
10-114	2547-2554	medical	_
10-115	2555-2568	complications	_
10-116	2569-2570	.	_

11-1	2571-2573	Of	_
11-2	2574-2577	the	_
11-3	2578-2580	40	_
11-4	2581-2593	participants	_
11-5	2594-2597	who	_
11-6	2598-2607	completed	_
11-7	2608-2611	the	_
11-8	2612-2620	scanning	_
11-9	2621-2626	visit	_
11-10	2627-2628	,	_
11-11	2629-2632	one	_
11-12	2633-2644	participant	_
11-13	2645-2648	was	_
11-14	2649-2657	excluded	_
11-15	2658-2661	due	_
11-16	2662-2664	to	_
11-17	2665-2668	the	_
11-18	2669-2672	use	_
11-19	2673-2675	of	_
11-20	2676-2677	a	_
11-21	2678-2686	narcotic	_
11-22	2687-2691	drug	_
11-23	2692-2696	that	_
11-24	2697-2708	compromised	_
11-25	2709-2712	her	_
11-26	2713-2722	alertness	_
11-27	2723-2729	during	_
11-28	2730-2733	the	_
11-29	2734-2739	visit	_
11-30	2740-2741	;	_
11-31	2742-2745	the	_
11-32	2746-2751	scans	_
11-33	2752-2754	of	_
11-34	2755-2760	three	_
11-35	2761-2771	additional	_
11-36	2772-2784	participants	_
11-37	2785-2789	were	_
11-38	2790-2799	discarded	_
11-39	2800-2803	due	_
11-40	2804-2806	to	_
11-41	2807-2813	motion	_
11-42	2814-2823	artifacts	_
11-43	2824-2827	and	_
11-44	2828-2837	technical	_
11-45	2838-2846	problems	_
11-46	2847-2848	.	_

12-1	2849-2855	Ethics	_
12-2	2856-2864	approval	_
12-3	2865-2868	for	_
12-4	2869-2873	this	_
12-5	2874-2879	study	_
12-6	2880-2883	was	_
12-7	2884-2891	granted	_
12-8	2892-2894	by	_
12-9	2895-2898	the	_
12-10	2899-2912	institutional	_
12-11	2913-2919	review	_
12-12	2920-2925	board	_
12-13	2926-2928	at	_
12-14	2929-2935	Baylor	_
12-15	2936-2943	College	_
12-16	2944-2946	of	_
12-17	2947-2955	Medicine	_
12-18	2956-2957	.	_

13-1	2958-2961	All	_
13-2	2962-2974	participants	_
13-3	2975-2983	provided	_
13-4	2984-2991	written	_
13-5	2992-3000	informed	_
13-6	3001-3008	consent	_
13-7	3009-3011	in	_
13-8	3012-3022	accordance	_
13-9	3023-3027	with	_
13-10	3028-3031	the	_
13-11	3032-3043	Declaration	_
13-12	3044-3046	of	_
13-13	3047-3055	Helsinki	_
13-14	3056-3057	.	_

14-1	3058-3063	Study	_
14-2	3064-3070	Design	_
14-3	3071-3078	Mothers	_
14-4	3079-3083	were	_
14-5	3084-3092	screened	_
14-6	3093-3096	for	_
14-7	3097-3102	study	_
14-8	3103-3113	enrollment	_
14-9	3114-3116	by	_
14-10	3117-3125	licensed	_
14-11	3126-3134	chemical	_
14-12	3135-3145	dependency	_
14-13	3146-3156	counselors	_
14-14	3157-3160	and	_
14-15	3161-3168	trained	_
14-16	3169-3177	research	_
14-17	3178-3188	assistants	_
14-18	3189-3193	upon	_
14-19	3194-3203	admission	_
14-20	3204-3206	to	_
14-21	3207-3210	the	_
14-22	3211-3220	treatment	_
14-23	3221-3229	facility	_
14-24	3230-3231	.	_

15-1	3232-3240	Eligible	_
15-2	3241-3244	and	_
15-3	3245-3253	enrolled	_
15-4	3254-3261	mothers	_
15-5	3262-3266	were	_
15-6	3267-3278	transported	_
15-7	3279-3281	to	_
15-8	3282-3285	the	_
15-9	3286-3296	Attachment	_
15-10	3297-3300	and	_
15-11	3301-3317	Neurodevelopment	_
15-12	3318-3328	Laboratory	_
15-13	3329-3332	for	_
15-14	3333-3338	study	_
15-15	3339-3345	visits	_
15-16	3346-3347	.	_

16-1	3348-3355	Infants	_
16-2	3356-3360	were	_
16-3	3361-3374	approximately	_
16-4	3375-3376	5	_
16-5	3377-3383	months	_
16-6	3384-3387	old	_
16-7	3388-3389	(	_
16-8	3390-3391	M	_
16-9	3392-3393	=	_
16-10	3394-3397	5.0	_
16-11	3398-3399	±	_
16-12	3400-3403	2.9	_
16-13	3404-3405	)	_
16-14	3406-3408	at	_
16-15	3409-3412	the	_
16-16	3413-3417	time	_
16-17	3418-3420	of	_
16-18	3421-3424	the	_
16-19	3425-3430	first	_
16-20	3431-3436	study	_
16-21	3437-3442	visit	_
16-22	3443-3444	,	_
16-23	3445-3447	at	_
16-24	3448-3453	which	_
16-25	3454-3458	time	_
16-26	3459-3465	infant	_
16-27	3466-3470	face	_
16-28	3471-3477	images	_
16-29	3478-3482	were	_
16-30	3483-3491	recorded	_
16-31	3492-3493	,	_
16-32	3494-3497	and	_
16-33	3498-3505	mothers	_
16-34	3506-3515	underwent	_
16-35	3516-3520	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
16-36	3521-3530	scanning2	_
16-37	3531-3533	at	_
16-38	3534-3547	approximately	_
16-39	3548-3549	6	_
16-40	3550-3556	months	_
16-41	3557-3558	(	_
16-42	3559-3560	M	_
16-43	3561-3562	=	_
16-44	3563-3566	6.0	_
16-45	3567-3568	±	_
16-46	3569-3572	3.4	_
16-47	3573-3574	)	_
16-48	3575-3585	postpartum	_
16-49	3586-3587	,	_
16-50	3588-3595	viewing	_
16-51	3596-3600	face	_
16-52	3601-3607	images	_
16-53	3608-3610	of	_
16-54	3611-3616	their	_
16-55	3617-3620	own	_
16-56	3621-3624	and	_
16-57	3625-3626	a	_
16-58	3627-3634	matched	_
16-59	3635-3642	unknown	_
16-60	3643-3649	infant	_
16-61	3650-3651	.	_

17-1	3652-3656	Upon	_
17-2	3657-3667	completion	_
17-3	3668-3670	of	_
17-4	3671-3674	the	_
17-5	3675-3679	scan	_
17-6	3680-3681	,	_
17-7	3682-3689	mothers	_
17-8	3690-3698	provided	_
17-9	3699-3706	ratings	_
17-10	3707-3709	on	_
17-11	3710-3713	how	_
17-12	3714-3718	they	_
17-13	3719-3728	perceived	_
17-14	3729-3732	the	_
17-15	3733-3739	infant	_
17-16	3740-3742	to	_
17-17	3743-3745	be	_
17-18	3746-3753	feeling	_
17-19	3754-3756	in	_
17-20	3757-3761	each	_
17-21	3762-3767	image	_
17-22	3768-3769	(	_
17-23	3770-3774	i.e.	_
17-24	3775-3776	,	_
17-25	3777-3782	happy	_
17-26	3783-3788	faces	_
17-27	3789-3790	:	_
17-28	3791-3792	“	_
17-29	3793-3796	how	_
17-30	3797-3802	happy	_
17-31	3803-3805	do	_
17-32	3806-3809	you	_
17-33	3810-3815	think	_
17-34	3816-3819	the	_
17-35	3820-3824	baby	_
17-36	3825-3828	was	_
17-37	3829-3836	feeling	_
17-38	3837-3838	?	_
17-39	3839-3840	”	_
17-40	3841-3842	;	_
17-41	3843-3846	sad	_
17-42	3847-3852	faces	_
17-43	3853-3854	:	_
17-44	3855-3856	“	_
17-45	3857-3860	how	_
17-46	3861-3864	sad	_
17-47	3865-3867	do	_
17-48	3868-3871	you	_
17-49	3872-3877	think	_
17-50	3878-3881	the	_
17-51	3882-3886	baby	_
17-52	3887-3890	was	_
17-53	3891-3898	feeling	_
17-54	3899-3900	?	_
17-55	3901-3902	”	_
17-56	3903-3906	and	_
17-57	3907-3908	“	_
17-58	3909-3912	how	_
17-59	3913-3923	distressed	_
17-60	3924-3926	do	_
17-61	3927-3930	you	_
17-62	3931-3936	think	_
17-63	3937-3940	the	_
17-64	3941-3945	baby	_
17-65	3946-3949	was	_
17-66	3950-3957	feeling	_
17-67	3958-3959	?	_
17-68	3960-3961	”	_
17-69	3962-3963	)	_
17-70	3964-3966	as	_
17-71	3967-3971	well	_
17-72	3972-3974	as	_
17-73	3975-3980	their	_
17-74	3981-3990	affective	_
17-75	3991-3999	response	_
17-76	4000-4002	to	_
17-77	4003-4010	viewing	_
17-78	4011-4015	each	_
17-79	4016-4022	infant	_
17-80	4023-4027	face	_
17-81	4028-4029	(	_
17-82	4030-4034	i.e.	_
17-83	4035-4036	,	_
17-84	4037-4042	happy	_
17-85	4043-4048	faces	_
17-86	4049-4050	:	_
17-87	4051-4052	“	_
17-88	4053-4056	how	_
17-89	4057-4062	happy	_
17-90	4063-4066	did	_
17-91	4067-4071	this	_
17-92	4072-4079	picture	_
17-93	4080-4084	make	_
17-94	4085-4088	you	_
17-95	4089-4093	feel	_
17-96	4094-4095	?	_
17-97	4096-4097	”	_
17-98	4098-4099	;	_
17-99	4100-4103	sad	_
17-100	4104-4109	faces	_
17-101	4110-4111	:	_
17-102	4112-4113	“	_
17-103	4114-4117	how	_
17-104	4118-4121	sad	_
17-105	4122-4125	did	_
17-106	4126-4130	this	_
17-107	4131-4138	picture	_
17-108	4139-4143	make	_
17-109	4144-4147	you	_
17-110	4148-4152	feel	_
17-111	4153-4154	?	_
17-112	4155-4156	”	_
17-113	4157-4160	and	_
17-114	4161-4162	“	_
17-115	4163-4166	how	_
17-116	4167-4177	distressed	_
17-117	4178-4181	did	_
17-118	4182-4186	this	_
17-119	4187-4194	picture	_
17-120	4195-4199	make	_
17-121	4200-4203	you	_
17-122	4204-4208	feel	_
17-123	4209-4210	?	_
17-124	4211-4212	”	_
17-125	4213-4214	)	_
17-126	4215-4216	.	_

18-1	4217-4227	Assessment	_
18-2	4228-4230	of	_
18-3	4231-4240	Substance	_
18-4	4241-4244	Use	_
18-5	4245-4247	We	_
18-6	4248-4252	used	_
18-7	4253-4256	the	_
18-8	4257-4261	MINI	_
18-9	4262-4264	to	_
18-10	4265-4271	assess	_
18-11	4272-4275	the	_
18-12	4276-4282	DSM-IV	_
18-13	4283-4292	diagnoses	_
18-14	4293-4295	of	_
18-15	4296-4309	substance-use	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder
18-16	4310-4319	disorders	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder
18-17	4320-4323	and	_
18-18	4324-4327	the	_
18-19	4328-4337	Addiction	http://maven.renci.org/NeuroBridge/neurobridge#AddictionSeverityIndex
18-20	4338-4346	Severity	http://maven.renci.org/NeuroBridge/neurobridge#AddictionSeverityIndex
18-21	4347-4352	Index	http://maven.renci.org/NeuroBridge/neurobridge#AddictionSeverityIndex
18-22	4353-4354	(	http://maven.renci.org/NeuroBridge/neurobridge#AddictionSeverityIndex
18-23	4355-4363	ASI-Lite	http://maven.renci.org/NeuroBridge/neurobridge#AddictionSeverityIndex
18-24	4364-4365	)	http://maven.renci.org/NeuroBridge/neurobridge#AddictionSeverityIndex
18-25	4366-4368	to	_
18-26	4369-4377	evaluate	_
18-27	4378-4381	the	_
18-28	4382-4388	nature	_
18-29	4389-4392	and	_
18-30	4393-4399	extent	_
18-31	4400-4402	of	_
18-32	4403-4407	past	_
18-33	4408-4411	and	_
18-34	4412-4419	present	_
18-35	4420-4429	substance	_
18-36	4430-4433	use	_
18-37	4434-4435	.	_

19-1	4436-4439	The	_
19-2	4440-4447	Alcohol	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
19-3	4448-4451	Use	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
19-4	4452-4461	Disorders	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
19-5	4462-4476	Identification	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
19-6	4477-4481	Test	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
19-7	4482-4483	(	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
19-8	4484-4489	AUDIT	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
19-9	4490-4491	;	_
19-10	4492-4497	Babor	_
19-11	4498-4500	et	_
19-12	4501-4504	al.	_
19-13	4505-4506	,	_
19-14	4507-4511	2001	_
19-15	4512-4513	)	_
19-16	4514-4517	and	_
19-17	4518-4521	the	_
19-18	4522-4532	Fagerstrom	http://maven.renci.org/NeuroBridge/neurobridge#FagerstromTestforNicotineDependence
19-19	4533-4537	Test	http://maven.renci.org/NeuroBridge/neurobridge#FagerstromTestforNicotineDependence
19-20	4538-4541	for	http://maven.renci.org/NeuroBridge/neurobridge#FagerstromTestforNicotineDependence
19-21	4542-4550	Nicotine	http://maven.renci.org/NeuroBridge/neurobridge#FagerstromTestforNicotineDependence
19-22	4551-4561	Dependence	http://maven.renci.org/NeuroBridge/neurobridge#FagerstromTestforNicotineDependence
19-23	4562-4563	(	http://maven.renci.org/NeuroBridge/neurobridge#FagerstromTestforNicotineDependence
19-24	4564-4568	FTND	http://maven.renci.org/NeuroBridge/neurobridge#FagerstromTestforNicotineDependence
19-25	4569-4570	;	_
19-26	4571-4581	Heatherton	_
19-27	4582-4584	et	_
19-28	4585-4588	al.	_
19-29	4589-4590	,	_
19-30	4591-4595	1991	_
19-31	4596-4597	)	_
19-32	4598-4602	were	_
19-33	4603-4607	used	_
19-34	4608-4610	to	_
19-35	4611-4618	measure	_
19-36	4619-4622	the	_
19-37	4623-4631	severity	_
19-38	4632-4634	of	_
19-39	4635-4642	alcohol	_
19-40	4643-4646	and	_
19-41	4647-4654	tobacco	_
19-42	4655-4658	use	_
19-43	4659-4660	,	_
19-44	4661-4673	respectively	_
19-45	4674-4675	.	_

20-1	4676-4681	Urine	_
20-2	4682-4692	toxicology	_
20-3	4693-4700	screens	_
20-4	4701-4704	and	_
20-5	4705-4712	alcohol	_
20-6	4713-4725	breathalyzer	_
20-7	4726-4731	tests	_
20-8	4732-4736	were	_
20-9	4737-4746	performed	_
20-10	4747-4749	at	_
20-11	4750-4753	the	_
20-12	4754-4760	outset	_
20-13	4761-4763	of	_
20-14	4764-4768	each	_
20-15	4769-4777	scanning	_
20-16	4778-4785	session	_
20-17	4786-4787	.	_

21-1	4788-4795	Stimuli	http://maven.renci.org/NeuroBridge/neurobridge#StimulantDependence
21-2	4796-4799	and	_
21-3	4800-4804	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol
21-4	4805-4813	Paradigm	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol
21-5	4814-4826	Experimental	_
21-6	4827-4834	stimuli	_
21-7	4835-4844	consisted	_
21-8	4845-4847	of	_
21-9	4848-4850	40	_
21-10	4851-4862	infant-face	_
21-11	4863-4869	images	_
21-12	4870-4874	from	_
21-13	4875-4879	four	_
21-14	4880-4892	experimental	_
21-15	4893-4903	conditions	_
21-16	4904-4905	:	_
21-17	4906-4908	10	_
21-18	4909-4918	own-happy	_
21-19	4919-4920	(	_
21-20	4921-4923	OH	_
21-21	4924-4925	)	_
21-22	4926-4927	,	_
21-23	4928-4930	10	_
21-24	4931-4944	unknown-happy	_
21-25	4945-4946	(	_
21-26	4947-4949	UH	_
21-27	4950-4951	)	_
21-28	4952-4953	,	_
21-29	4954-4956	10	_
21-30	4957-4964	own-sad	_
21-31	4965-4966	(	_
21-32	4967-4969	OS	_
21-33	4970-4971	)	_
21-34	4972-4973	,	_
21-35	4974-4977	and	_
21-36	4978-4980	10	_
21-37	4981-4992	unknown-sad	_
21-38	4993-4994	(	_
21-39	4995-4997	US	_
21-40	4998-4999	)	_
21-41	5000-5006	infant	_
21-42	5007-5012	faces	_
21-43	5013-5014	(	_
21-44	5015-5021	Figure	_
21-45	5022-5023	2	_
21-46	5024-5025	)	_
21-47	5026-5027	.	_

22-1	5028-5031	For	_
22-2	5032-5036	each	_
22-3	5037-5043	mother	_
22-4	5044-5045	,	_
22-5	5046-5051	still	_
22-6	5052-5056	face	_
22-7	5057-5063	images	_
22-8	5064-5068	were	_
22-9	5069-5077	captured	_
22-10	5078-5082	from	_
22-11	5083-5086	the	_
22-12	5087-5093	videos	_
22-13	5094-5102	recorded	_
22-14	5103-5105	of	_
22-15	5106-5109	her	_
22-16	5110-5113	own	_
22-17	5114-5120	infant	_
22-18	5121-5124	and	_
22-19	5125-5127	of	_
22-20	5128-5129	a	_
22-21	5130-5136	single	_
22-22	5137-5144	unknown	_
22-23	5145-5151	infant	_
22-24	5152-5159	matched	_
22-25	5160-5162	on	_
22-26	5163-5166	age	_
22-27	5167-5168	,	_
22-28	5169-5173	race	_
22-29	5174-5175	,	_
22-30	5176-5179	and	_
22-31	5180-5186	affect	_
22-32	5187-5196	intensity	_
22-33	5197-5198	(	_
22-34	5199-5202	and	_
22-35	5203-5206	sex	_
22-36	5207-5208	,	_
22-37	5209-5211	if	_
22-38	5212-5227	distinguishable	_
22-39	5228-5229	)	_
22-40	5230-5231	.	_

23-1	5232-5235	The	_
23-2	5236-5251	video-recording	_
23-3	5252-5255	was	_
23-4	5256-5266	undertaken	_
23-5	5267-5269	at	_
23-6	5270-5273	the	_
23-7	5274-5284	laboratory	_
23-8	5285-5298	approximately	_
23-9	5299-5300	5	_
23-10	5301-5307	months	_
23-11	5308-5318	postpartum	_
23-12	5319-5320	,	_
23-13	5321-5326	while	_
23-14	5327-5336	eliciting	_
23-15	5337-5342	happy	_
23-16	5343-5346	and	_
23-17	5347-5350	sad	_
23-18	5351-5362	expressions	_
23-19	5363-5367	from	_
23-20	5368-5372	each	_
23-21	5373-5379	infant	_
23-22	5380-5381	.	_

24-1	5382-5385	Two	_
24-2	5386-5393	trained	_
24-3	5394-5400	raters	_
24-4	5401-5405	with	_
24-5	5406-5417	established	_
24-6	5418-5429	reliability	_
24-7	5430-5431	(	_
24-8	5432-5437	kappa	_
24-9	5438-5439	=	_
24-10	5440-5444	.954	_
24-11	5445-5446	,	_
24-12	5447-5448	p	_
24-13	5449-5450	<	_
24-14	5451-5455	.001	_
24-15	5456-5457	)	_
24-16	5458-5468	classified	_
24-17	5469-5474	still	_
24-18	5475-5479	face	_
24-19	5480-5486	images	_
24-20	5487-5491	into	_
24-21	5492-5495	one	_
24-22	5496-5498	of	_
24-23	5499-5503	four	_
24-24	5504-5510	affect	_
24-25	5511-5517	groups	_
24-26	5518-5523	based	_
24-27	5524-5526	on	_
24-28	5527-5534	valence	_
24-29	5535-5538	and	_
24-30	5539-5548	intensity	_
24-31	5549-5550	(	_
24-32	5551-5554	see	_
24-33	5555-5556	)	_
24-34	5557-5558	,	_
24-35	5559-5564	which	_
24-36	5565-5573	provided	_
24-37	5574-5577	the	_
24-38	5578-5583	basis	_
24-39	5584-5587	for	_
24-40	5588-5591	the	_
24-41	5592-5600	matching	_
24-42	5601-5608	between	_
24-43	5609-5612	own	_
24-44	5613-5616	and	_
24-45	5617-5624	unknown	_
24-46	5625-5631	infant	_
24-47	5632-5637	faces	_
24-48	5638-5639	.	_

25-1	5640-5643	The	_
25-2	5644-5652	adequacy	_
25-3	5653-5655	of	_
25-4	5656-5670	classification	_
25-5	5671-5674	and	_
25-6	5675-5683	matching	_
25-7	5684-5687	was	_
25-8	5688-5697	confirmed	_
25-9	5698-5700	by	_
25-10	5701-5706	three	_
25-11	5707-5718	independent	_
25-12	5719-5725	female	_
25-13	5726-5732	raters	_
25-14	5733-5734	,	_
25-15	5735-5738	who	_
25-16	5739-5751	demonstrated	_
25-17	5752-5756	that	_
25-18	5757-5760	own	_
25-19	5761-5764	and	_
25-20	5765-5772	unknown	_
25-21	5773-5779	infant	_
25-22	5780-5784	face	_
25-23	5785-5791	images	_
25-24	5792-5795	did	_
25-25	5796-5799	not	_
25-26	5800-5806	differ	_
25-27	5807-5809	in	_
25-28	5810-5815	terms	_
25-29	5816-5818	of	_
25-30	5819-5825	affect	_
25-31	5826-5835	intensity	_
25-32	5836-5837	(	_
25-33	5838-5841	MOH	_
25-34	5842-5843	=	_
25-35	5844-5848	4.20	_
25-36	5849-5850	±	_
25-37	5851-5855	0.03	_
25-38	5856-5857	,	_
25-39	5858-5861	MUH	_
25-40	5862-5863	=	_
25-41	5864-5868	4.25	_
25-42	5869-5870	±	_
25-43	5871-5875	0.02	_
25-44	5876-5877	,	_
25-45	5878-5879	p	_
25-46	5880-5881	=	_
25-47	5882-5885	.11	_
25-48	5886-5887	;	_
25-49	5888-5891	MOS	_
25-50	5892-5893	=	_
25-51	5894-5898	1.50	_
25-52	5899-5900	±	_
25-53	5901-5905	0.04	_
25-54	5906-5907	,	_
25-55	5908-5911	MUS	_
25-56	5912-5913	=	_
25-57	5914-5918	1.55	_
25-58	5919-5920	±	_
25-59	5921-5925	0.04	_
25-60	5926-5927	,	_
25-61	5928-5929	p	_
25-62	5930-5931	=	_
25-63	5932-5935	.48	_
25-64	5936-5937	)	_
25-65	5938-5939	.	_

26-1	5940-5942	Of	_
26-2	5943-5946	the	_
26-3	5947-5949	40	_
26-4	5950-5955	total	_
26-5	5956-5962	images	_
26-6	5963-5964	,	_
26-7	5965-5967	12	_
26-8	5968-5971	own	_
26-9	5972-5973	(	_
26-10	5974-5978	i.e.	_
26-11	5979-5980	,	_
26-12	5981-5982	6	_
26-13	5983-5985	OH	_
26-14	5986-5989	and	_
26-15	5990-5991	6	_
26-16	5992-5994	OS	_
26-17	5995-5996	)	_
26-18	5997-6000	and	_
26-19	6001-6003	12	_
26-20	6004-6011	unknown	_
26-21	6012-6013	(	_
26-22	6014-6018	i.e.	_
26-23	6019-6020	,	_
26-24	6021-6022	6	_
26-25	6023-6025	UH	_
26-26	6026-6029	and	_
26-27	6030-6031	6	_
26-28	6032-6034	US	_
26-29	6035-6036	)	_
26-30	6037-6043	infant	_
26-31	6044-6048	face	_
26-32	6049-6055	images	_
26-33	6056-6060	were	_
26-34	6061-6069	selected	_
26-35	6070-6073	for	_
26-36	6074-6077	use	_
26-37	6078-6080	in	_
26-38	6081-6085	each	_
26-39	6086-6088	of	_
26-40	6089-6092	the	_
26-41	6093-6096	two	_
26-42	6097-6107	functional	_
26-43	6108-6112	runs	_
26-44	6113-6114	.	_

27-1	6115-6118	Cry	_
27-2	6119-6126	stimuli	_
27-3	6127-6131	were	_
27-4	6132-6136	also	_
27-5	6137-6145	randomly	_
27-6	6146-6158	interspersed	_
27-7	6159-6163	with	_
27-8	6164-6167	the	_
27-9	6168-6172	face	_
27-10	6173-6179	images	_
27-11	6180-6181	,	_
27-12	6182-6185	but	_
27-13	6186-6190	were	_
27-14	6191-6194	not	_
27-15	6195-6198	the	_
27-16	6199-6206	subject	_
27-17	6207-6209	of	_
27-18	6210-6213	the	_
27-19	6214-6221	current	_
27-20	6222-6227	paper	_
27-21	6228-6229	.	_

28-1	6230-6233	The	_
28-2	6234-6238	face	_
28-3	6239-6245	images	_
28-4	6246-6250	were	_
28-5	6251-6263	standardized	_
28-6	6264-6267	for	_
28-7	6268-6272	size	_
28-8	6273-6274	(	_
28-9	6275-6278	4.5	_
28-10	6279-6285	inches	_
28-11	6286-6288	in	_
28-12	6289-6295	height	_
28-13	6296-6297	)	_
28-14	6298-6299	,	_
28-15	6300-6308	adjusted	_
28-16	6309-6312	for	_
28-17	6313-6323	luminosity	_
28-18	6324-6327	and	_
28-19	6328-6336	contrast	_
28-20	6337-6338	,	_
28-21	6339-6348	displayed	_
28-22	6349-6356	against	_
28-23	6357-6358	a	_
28-24	6359-6363	gray	_
28-25	6364-6374	background	_
28-26	6375-6376	,	_
28-27	6377-6380	and	_
28-28	6381-6390	projected	_
28-29	6391-6395	onto	_
28-30	6396-6398	an	_
28-31	6399-6407	overhead	_
28-32	6408-6414	mirror	_
28-33	6415-6422	display	_
28-34	6423-6426	for	_
28-35	6427-6439	presentation	_
28-36	6440-6442	to	_
28-37	6443-6450	mothers	_
28-38	6451-6457	during	_
28-39	6458-6466	scanning	_
28-40	6467-6468	.	_

29-1	6469-6472	All	_
29-2	6473-6479	images	_
29-3	6480-6488	appeared	_
29-4	6489-6491	in	_
29-5	6492-6493	a	_
29-6	6494-6506	pseudorandom	_
29-7	6507-6515	sequence	_
29-8	6516-6520	with	_
29-9	6521-6522	a	_
29-10	6523-6531	stimulus	_
29-11	6532-6540	duration	_
29-12	6541-6543	of	_
29-13	6544-6545	2	_
29-14	6546-6553	seconds	_
29-15	6554-6557	and	_
29-16	6558-6559	a	_
29-17	6560-6566	random	_
29-18	6567-6581	inter-stimulus	_
29-19	6582-6590	interval	_
29-20	6591-6593	of	_
29-21	6594-6595	2	_
29-22	6596-6598	to	_
29-23	6599-6601	11	_
29-24	6602-6609	seconds	_
29-25	6610-6611	.	_

30-1	6612-6616	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
30-2	6617-6621	Data	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
30-3	6622-6633	Acquisition	_
30-4	6634-6641	Imaging	_
30-5	6642-6646	data	_
30-6	6647-6651	were	_
30-7	6652-6660	acquired	_
30-8	6661-6666	using	_
30-9	6667-6668	a	_
30-10	6669-6676	3-Tesla	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
30-11	6677-6684	Siemens	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
30-12	6685-6689	Trio	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
30-13	6690-6693	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
30-14	6694-6700	system	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
30-15	6701-6702	(	_
30-16	6703-6711	Erlangen	_
30-17	6712-6713	,	_
30-18	6714-6721	Germany	_
30-19	6722-6723	)	_
30-20	6724-6728	with	_
30-21	6729-6730	a	_
30-22	6731-6739	standard	_
30-23	6740-6750	12-channel	_
30-24	6751-6755	head	_
30-25	6756-6760	coil	_
30-26	6761-6762	.	_

31-1	6763-6772	Localizer	_
31-2	6773-6779	images	_
31-3	6780-6784	were	_
31-4	6785-6793	acquired	_
31-5	6794-6797	for	_
31-6	6798-6809	prescribing	_
31-7	6810-6813	the	_
31-8	6814-6824	functional	_
31-9	6825-6830	image	_
31-10	6831-6838	volumes	_
31-11	6839-6847	parallel	_
31-12	6848-6850	to	_
31-13	6851-6854	the	_
31-14	6855-6871	intercommissural	_
31-15	6872-6876	line	_
31-16	6877-6878	.	_

32-1	6879-6889	Functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
32-2	6890-6896	images	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
32-3	6897-6901	were	_
32-4	6902-6910	obtained	_
32-5	6911-6916	using	_
32-6	6917-6918	a	_
32-7	6919-6932	gradient-echo	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
32-8	6933-6944	echo-planar	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
32-9	6945-6952	imaging	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
32-10	6953-6954	(	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
32-11	6955-6958	EPI	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
32-12	6959-6960	)	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
32-13	6961-6969	sequence	_
32-14	6970-6971	(	_
32-15	6972-6974	32	_
32-16	6975-6988	axial-oblique	_
32-17	6989-6995	slices	_
32-18	6996-6997	;	_
32-19	6998-7008	repetition	_
32-20	7009-7013	time	_
32-21	7014-7015	[	_
32-22	7016-7018	TR	_
32-23	7019-7020	]	_
32-24	7021-7022	,	_
32-25	7023-7027	2000	_
32-26	7028-7030	ms	_
32-27	7031-7032	;	_
32-28	7033-7037	echo	_
32-29	7038-7042	time	_
32-30	7043-7044	[	_
32-31	7045-7047	TE	_
32-32	7048-7049	]	_
32-33	7050-7051	,	_
32-34	7052-7054	30	_
32-35	7055-7057	ms	_
32-36	7058-7059	;	_
32-37	7060-7064	flip	_
32-38	7065-7070	angle	_
32-39	7071-7072	[	_
32-40	7073-7075	FA	_
32-41	7076-7077	]	_
32-42	7078-7079	,	_
32-43	7080-7083	80°	_
32-44	7084-7085	;	_
32-45	7086-7091	field	_
32-46	7092-7094	of	_
32-47	7095-7099	view	_
32-48	7100-7101	[	_
32-49	7102-7105	FOV	_
32-50	7106-7107	]	_
32-51	7108-7109	,	_
32-52	7110-7113	220	_
32-53	7114-7116	mm	_
32-54	7117-7118	x	_
32-55	7119-7122	220	_
32-56	7123-7125	mm	_
32-57	7126-7127	;	_
32-58	7128-7134	matrix	_
32-59	7135-7136	,	_
32-60	7137-7139	64	_
32-61	7140-7141	x	_
32-62	7142-7144	64	_
32-63	7145-7146	;	_
32-64	7147-7155	in-plane	_
32-65	7156-7166	resolution	_
32-66	7167-7168	,	_
32-67	7169-7172	3.4	_
32-68	7173-7175	mm	_
32-69	7176-7177	x	_
32-70	7178-7181	3.4	_
32-71	7182-7184	mm	_
32-72	7185-7186	;	_
32-73	7187-7192	slice	_
32-74	7193-7202	thickness	_
32-75	7203-7204	,	_
32-76	7205-7206	4	_
32-77	7207-7209	mm	_
32-78	7210-7211	)	_
32-79	7212-7213	,	_
32-80	7214-7223	resulting	_
32-81	7224-7226	in	_
32-82	7227-7230	121	_
32-83	7231-7237	images	_
32-84	7238-7247	collected	_
32-85	7248-7251	per	_
32-86	7252-7256	4:06	_
32-87	7257-7260	min	_
32-88	7261-7271	functional	_
32-89	7272-7275	run	_
32-90	7276-7277	.	_

33-1	7278-7281	Two	_
33-2	7282-7287	types	_
33-3	7288-7290	of	_
33-4	7291-7301	anatomical	_
33-5	7302-7308	images	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
33-6	7309-7313	were	_
33-7	7314-7322	acquired	_
33-8	7323-7324	:	_
33-9	7325-7327	T1	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
33-10	7328-7336	weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
33-11	7337-7345	anatomic	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
33-12	7346-7350	scan	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
33-13	7351-7356	using	_
33-14	7357-7358	a	_
33-15	7359-7363	fast	_
33-16	7364-7373	low-angle	_
33-17	7374-7378	shot	_
33-18	7379-7380	(	_
33-19	7381-7386	FLASH	_
33-20	7387-7388	)	_
33-21	7389-7397	sequence	_
33-22	7398-7399	(	_
33-23	7400-7402	40	_
33-24	7403-7411	sagittal	_
33-25	7412-7418	slices	_
33-26	7419-7420	;	_
33-27	7421-7423	TR	_
33-28	7424-7425	,	_
33-29	7426-7428	20	_
33-30	7429-7431	ms	_
33-31	7432-7433	;	_
33-32	7434-7436	TE	_
33-33	7437-7438	,	_
33-34	7439-7443	6.86	_
33-35	7444-7446	ms	_
33-36	7447-7448	;	_
33-37	7449-7451	FA	_
33-38	7452-7453	,	_
33-39	7454-7457	25°	_
33-40	7458-7459	;	_
33-41	7460-7463	FOV	_
33-42	7464-7465	,	_
33-43	7466-7469	240	_
33-44	7470-7472	mm	_
33-45	7473-7474	x	_
33-46	7475-7478	240	_
33-47	7479-7481	mm	_
33-48	7482-7483	;	_
33-49	7484-7490	matrix	_
33-50	7491-7492	,	_
33-51	7493-7496	256	_
33-52	7497-7498	x	_
33-53	7499-7502	241	_
33-54	7503-7504	;	_
33-55	7505-7513	in-plane	_
33-56	7514-7524	resolution	_
33-57	7525-7526	,	_
33-58	7527-7530	1.0	_
33-59	7531-7533	mm	_
33-60	7534-7535	x	_
33-61	7536-7539	0.9	_
33-62	7540-7542	mm	_
33-63	7543-7544	;	_
33-64	7545-7550	slice	_
33-65	7551-7560	thickness	_
33-66	7561-7562	,	_
33-67	7563-7564	4	_
33-68	7565-7567	mm	_
33-69	7568-7569	)	_
33-70	7570-7573	and	_
33-71	7574-7589	high-resolution	_
33-72	7590-7598	anatomic	_
33-73	7599-7603	scan	http://maven.renci.org/NeuroBridge/neurobridge#ComputedTomographyScan
33-74	7604-7609	using	_
33-75	7610-7611	a	_
33-76	7612-7634	magnetization-prepared	_
33-77	7635-7640	rapid	_
33-78	7641-7649	gradient	_
33-79	7650-7654	echo	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
33-80	7655-7656	(	_
33-81	7657-7663	MPRAGE	_
33-82	7664-7665	)	http://maven.renci.org/NeuroBridge/neurobridge#Thing
33-83	7666-7674	sequence	_
33-84	7675-7676	(	_
33-85	7677-7680	176	_
33-86	7681-7689	sagittal	_
33-87	7690-7696	slices	_
33-88	7697-7698	;	_
33-89	7699-7701	TR	_
33-90	7702-7703	,	_
33-91	7704-7708	2530	_
33-92	7709-7711	ms	_
33-93	7712-7713	;	_
33-94	7714-7716	TE	_
33-95	7717-7718	,	_
33-96	7719-7723	2.43	_
33-97	7724-7726	ms	_
33-98	7727-7728	;	_
33-99	7729-7731	FA	_
33-100	7732-7733	,	_
33-101	7734-7736	7°	_
33-102	7737-7738	;	_
33-103	7739-7742	FOV	_
33-104	7743-7744	,	_
33-105	7745-7748	256	_
33-106	7749-7751	mm	_
33-107	7752-7753	×	_
33-108	7754-7757	256	_
33-109	7758-7760	mm	_
33-110	7761-7762	;	_
33-111	7763-7769	matrix	_
33-112	7770-7771	,	_
33-113	7772-7775	256	_
33-114	7776-7777	×	_
33-115	7778-7781	246	_
33-116	7782-7783	;	_
33-117	7784-7792	in-plane	_
33-118	7793-7803	resolution	_
33-119	7804-7805	,	_
33-120	7806-7809	1.0	_
33-121	7810-7812	mm	_
33-122	7813-7814	×	_
33-123	7815-7818	1.0	_
33-124	7819-7821	mm	_
33-125	7822-7823	;	_
33-126	7824-7829	slice	_
33-127	7830-7839	thickness	_
33-128	7840-7841	,	_
33-129	7842-7843	1	_
33-130	7844-7846	mm	_
33-131	7847-7848	)	_
33-132	7849-7852	for	_
33-133	7853-7855	3D	_
33-134	7856-7870	reconstruction	_
33-135	7871-7872	.	_

34-1	7873-7877	Data	_
34-2	7878-7886	Analysis	_
34-3	7887-7891	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
34-4	7892-7900	analysis	_
34-5	7901-7914	Preprocessing	_
34-6	7915-7918	and	_
34-7	7919-7927	analyses	_
34-8	7928-7930	of	_
34-9	7931-7934	the	_
34-10	7935-7939	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
34-11	7940-7944	data	_
34-12	7945-7949	were	_
34-13	7950-7959	performed	_
34-14	7960-7965	using	_
34-15	7966-7978	BrainVoyager	_
34-16	7979-7981	QX	_
34-17	7982-7983	,	_
34-18	7984-7991	version	_
34-19	7992-7997	2.3.1	_
34-20	7998-7999	(	_
34-21	8000-8005	Brain	_
34-22	8006-8016	Innovation	_
34-23	8017-8018	,	_
34-24	8019-8029	Maastricht	_
34-25	8030-8031	,	_
34-26	8032-8035	The	_
34-27	8036-8047	Netherlands	_
34-28	8048-8049	)	_
34-29	8050-8051	.	_

35-1	8052-8057	Prior	_
35-2	8058-8060	to	_
35-3	8061-8069	analysis	_
35-4	8070-8071	,	_
35-5	8072-8077	blood	_
35-6	8078-8089	oxygenation	_
35-7	8090-8105	level-dependent	_
35-8	8106-8107	(	_
35-9	8108-8112	BOLD	_
35-10	8113-8114	)	_
35-11	8115-8121	images	_
35-12	8122-8126	were	_
35-13	8127-8136	corrected	_
35-14	8137-8140	for	_
35-15	8141-8146	slice	_
35-16	8147-8153	timing	_
35-17	8154-8157	and	_
35-18	8158-8167	realigned	_
35-19	8168-8170	to	_
35-20	8171-8174	the	_
35-21	8175-8180	first	_
35-22	8181-8187	volume	_
35-23	8188-8191	for	_
35-24	8192-8196	head	_
35-25	8197-8203	motion	_
35-26	8204-8214	correction	_
35-27	8215-8216	.	_

36-1	8217-8221	Head	_
36-2	8222-8228	motion	_
36-3	8229-8231	of	_
36-4	8232-8233	<	_
36-5	8234-8237	2.0	_
36-6	8238-8240	mm	_
36-7	8241-8252	translation	_
36-8	8253-8255	or	_
36-9	8256-8260	2.0°	_
36-10	8261-8269	rotation	_
36-11	8270-8273	was	_
36-12	8274-8280	deemed	_
36-13	8281-8291	acceptable	_
36-14	8292-8293	.	_

37-1	8294-8301	Spatial	_
37-2	8302-8311	smoothing	_
37-3	8312-8315	was	_
37-4	8316-8325	performed	_
37-5	8326-8330	with	_
37-6	8331-8332	a	_
37-7	8333-8334	4	_
37-8	8335-8337	mm	_
37-9	8338-8342	full	_
37-10	8343-8348	width	_
37-11	8349-8351	at	_
37-12	8352-8356	half	_
37-13	8357-8364	maximum	_
37-14	8365-8366	(	_
37-15	8367-8371	FWHM	_
37-16	8372-8373	)	_
37-17	8374-8382	Gaussian	_
37-18	8383-8389	kernel	_
37-19	8390-8391	,	_
37-20	8392-8400	followed	_
37-21	8401-8403	by	_
37-22	8404-8413	high-pass	_
37-23	8414-8423	filtering	_
37-24	8424-8429	using	_
37-25	8430-8431	a	_
37-26	8432-8439	Fourier	_
37-27	8440-8445	basis	_
37-28	8446-8449	set	_
37-29	8450-8452	of	_
37-30	8453-8456	two	_
37-31	8457-8463	cycles	_
37-32	8464-8467	per	_
37-33	8468-8471	run	_
37-34	8472-8474	to	_
37-35	8475-8481	remove	_
37-36	8482-8485	low	_
37-37	8486-8495	frequency	_
37-38	8496-8502	drifts	_
37-39	8503-8504	.	_

38-1	8505-8515	Functional	_
38-2	8516-8520	data	_
38-3	8521-8525	were	_
38-4	8526-8530	then	_
38-5	8531-8544	co-registered	_
38-6	8545-8549	with	_
38-7	8550-8553	the	_
38-8	8554-8564	anatomical	_
38-9	8565-8569	data	_
38-10	8570-8571	,	_
38-11	8572-8583	transformed	_
38-12	8584-8588	into	_
38-13	8589-8590	3	_
38-14	8591-8592	x	_
38-15	8593-8594	3	_
38-16	8595-8596	x	_
38-17	8597-8598	3	_
38-18	8599-8601	mm	_
38-19	8602-8611	isotropic	_
38-20	8612-8618	voxels	_
38-21	8619-8620	,	_
38-22	8621-8624	and	_
38-23	8625-8635	normalized	_
38-24	8636-8640	into	_
38-25	8641-8644	the	_
38-26	8645-8654	Talairach	_
38-27	8655-8660	space	_
38-28	8661-8662	.	_

39-1	8663-8666	For	_
39-2	8667-8671	each	_
39-3	8672-8675	run	_
39-4	8676-8678	of	_
39-5	8679-8683	each	_
39-6	8684-8691	subject	_
39-7	8692-8696	data	_
39-8	8697-8698	,	_
39-9	8699-8700	a	_
39-10	8701-8708	general	_
39-11	8709-8715	linear	_
39-12	8716-8721	model	_
39-13	8722-8723	(	_
39-14	8724-8727	GLM	_
39-15	8728-8729	)	_
39-16	8730-8733	was	_
39-17	8734-8743	specified	_
39-18	8744-8745	,	_
39-19	8746-8754	modeling	_
39-20	8755-8758	the	_
39-21	8759-8763	BOLD	_
39-22	8764-8770	signal	_
39-23	8771-8777	change	_
39-24	8778-8781	for	_
39-25	8782-8786	each	_
39-26	8787-8799	experimental	_
39-27	8800-8809	condition	_
39-28	8810-8811	(	_
39-29	8812-8814	OH	_
39-30	8815-8816	,	_
39-31	8817-8819	UH	_
39-32	8820-8821	,	_
39-33	8822-8824	OS	_
39-34	8825-8826	,	_
39-35	8827-8830	and	_
39-36	8831-8833	US	_
39-37	8834-8835	)	_
39-38	8836-8841	using	_
39-39	8842-8843	a	_
39-40	8844-8856	double-gamma	_
39-41	8857-8868	hemodynamic	_
39-42	8869-8877	response	_
39-43	8878-8886	function	_
39-44	8887-8888	.	_

40-1	8889-8891	In	_
40-2	8892-8897	order	_
40-3	8898-8900	to	_
40-4	8901-8907	adjust	_
40-5	8908-8911	for	_
40-6	8912-8918	signal	_
40-7	8919-8928	magnitude	_
40-8	8929-8940	variability	_
40-9	8941-8944	and	_
40-10	8945-8955	facilitate	_
40-11	8956-8967	comparisons	_
40-12	8968-8972	with	_
40-13	8973-8978	other	_
40-14	8979-8987	research	_
40-15	8988-8989	(	_
40-16	8990-8994	e.g.	_
40-17	8995-8996	,	_
40-18	8997-8998	)	_
40-19	8999-9000	,	_
40-20	9001-9004	the	_
40-21	9005-9014	resulting	_
40-22	9015-9025	regression	_
40-23	9026-9033	weights	_
40-24	9034-9035	(	_
40-25	9036-9037	β	_
40-26	9038-9039	)	_
40-27	9040-9044	were	_
40-28	9045-9049	then	_
40-29	9050-9057	percent	_
40-30	9058-9068	normalized	_
40-31	9069-9071	to	_
40-32	9072-9079	reflect	_
40-33	9080-9087	percent	_
40-34	9088-9094	signal	_
40-35	9095-9101	change	_
40-36	9102-9105	and	_
40-37	9106-9118	concatenated	_
40-38	9119-9125	across	_
40-39	9126-9129	the	_
40-40	9130-9136	entire	_
40-41	9137-9142	group	_
40-42	9143-9145	of	_
40-43	9146-9148	36	_
40-44	9149-9157	subjects	_
40-45	9158-9161	for	_
40-46	9162-9174	second-level	_
40-47	9175-9189	random-effects	_
40-48	9190-9198	analyses	_
40-49	9199-9200	.	_

41-1	9201-9206	Group	_
41-2	9207-9213	t-maps	_
41-3	9214-9218	were	_
41-4	9219-9228	generated	_
41-5	9229-9241	representing	_
41-6	9242-9249	percent	_
41-7	9250-9254	BOLD	_
41-8	9255-9264	contrasts	_
41-9	9265-9272	between	_
41-10	9273-9276	own	_
41-11	9277-9280	and	_
41-12	9281-9288	unknown	_
41-13	9289-9295	infant	_
41-14	9296-9306	conditions	_
41-15	9307-9308	:	_
41-16	9309-9311	OH	_
41-17	9312-9314	vs	_
41-18	9315-9316	.	_

42-1	9317-9319	UH	_
42-2	9320-9323	and	_
42-3	9324-9326	OS	_
42-4	9327-9329	vs	_
42-5	9330-9331	.	_

43-1	9332-9334	US	_
43-2	9335-9336	.	_

44-1	9337-9345	Analyses	_
44-2	9346-9350	were	_
44-3	9351-9360	performed	_
44-4	9361-9363	at	_
44-5	9364-9367	two	_
44-6	9368-9374	levels	_
44-7	9375-9376	:	_
44-8	9377-9382	first	_
44-9	9383-9388	using	_
44-10	9389-9390	a	_
44-11	9391-9402	whole-brain	_
44-12	9403-9413	voxel-wise	_
44-13	9414-9422	analysis	_
44-14	9423-9424	,	_
44-15	9425-9433	followed	_
44-16	9434-9436	by	_
44-17	9437-9438	a	_
44-18	9439-9457	region-of-interest	_
44-19	9458-9466	analysis	_
44-20	9467-9469	of	_
44-21	9470-9473	the	_
44-22	9474-9483	bilateral	_
44-23	9484-9492	striatum	_
44-24	9493-9495	to	_
44-25	9496-9504	evaluate	_
44-26	9505-9520	within-striatal	_
44-27	9521-9532	differences	_
44-28	9533-9535	in	_
44-29	9536-9543	percent	_
44-30	9544-9548	BOLD	_
44-31	9549-9556	signals	_
44-32	9557-9559	to	_
44-33	9560-9563	our	_
44-34	9564-9572	contrast	_
44-35	9573-9575	of	_
44-36	9576-9584	interest	_
44-37	9585-9586	.	_

45-1	9587-9590	The	_
45-2	9591-9599	striatum	_
45-3	9600-9603	was	_
45-4	9604-9612	selected	_
45-5	9613-9625	structurally	_
45-6	9626-9627	,	_
45-7	9628-9633	based	_
45-8	9634-9636	on	_
45-9	9637-9638	a	_
45-10	9639-9643	mask	_
45-11	9644-9651	derived	_
45-12	9652-9656	from	_
45-13	9657-9660	the	_
45-14	9661-9672	subcortical	_
45-15	9673-9678	atlas	_
45-16	9679-9681	of	_
45-17	9682-9685	the	_
45-18	9686-9691	Brain	_
45-19	9692-9697	Tutor	_
45-20	9698-9700	HD	_
45-21	9701-9702	,	_
45-22	9703-9710	version	_
45-23	9711-9714	2.2	_
45-24	9715-9716	(	_
45-25	9717-9722	Brain	_
45-26	9723-9733	Innovation	_
45-27	9734-9735	,	_
45-28	9736-9746	Maastricht	_
45-29	9747-9748	,	_
45-30	9749-9752	The	_
45-31	9753-9764	Netherlands	_
45-32	9765-9766	)	_
45-33	9767-9768	,	_
45-34	9769-9772	and	_
45-35	9773-9782	comprised	_
45-36	9783-9786	289	_
45-37	9787-9790	and	_
45-38	9791-9794	302	_
45-39	9795-9801	voxels	_
45-40	9802-9805	for	_
45-41	9806-9809	the	_
45-42	9810-9814	left	_
45-43	9815-9818	and	_
45-44	9819-9824	right	_
45-45	9825-9826	,	_
45-46	9827-9839	respectively	_
45-47	9840-9841	.	_

46-1	9842-9850	Post-hoc	_
46-2	9851-9862	examination	_
46-3	9863-9865	of	_
46-4	9866-9877	whole-brain	_
46-5	9878-9886	analysis	_
46-6	9887-9894	results	_
46-7	9895-9898	was	_
46-8	9899-9908	conducted	_
46-9	9909-9911	by	_
46-10	9912-9922	extracting	_
46-11	9923-9930	percent	_
46-12	9931-9937	signal	_
46-13	9938-9944	change	_
46-14	9945-9951	values	_
46-15	9952-9955	for	_
46-16	9956-9958	OH	_
46-17	9959-9962	and	_
46-18	9963-9965	UH	_
46-19	9966-9970	from	_
46-20	9971-9976	cubes	_
46-21	9977-9985	centered	_
46-22	9986-9988	at	_
46-23	9989-9994	local	_
46-24	9995-10000	peaks	_
46-25	10001-10007	within	_
46-26	10008-10011	the	_
46-27	10012-10019	cluster	_
46-28	10020-10022	of	_
46-29	10023-10024	(	_
46-30	10025-10027	de	_
46-31	10028-10029	)	_
46-32	10030-10040	activation	_
46-33	10041-10044	and	_
46-34	10045-10054	extending	_
46-35	10055-10057	up	_
46-36	10058-10060	to	_
46-37	10061-10062	±	_
46-38	10063-10065	10	_
46-39	10066-10072	voxels	_
46-40	10073-10076	per	_
46-41	10077-10086	dimension	_
46-42	10087-10088	,	_
46-43	10089-10095	unless	_
46-44	10096-10103	limited	_
46-45	10104-10106	by	_
46-46	10107-10110	the	_
46-47	10111-10118	spatial	_
46-48	10119-10125	extent	_
46-49	10126-10128	of	_
46-50	10129-10130	(	_
46-51	10131-10133	de	_
46-52	10134-10135	)	_
46-53	10136-10146	activation	_
46-54	10147-10148	.	_

47-1	10149-10153	This	_
47-2	10154-10161	allowed	_
47-3	10162-10164	us	_
47-4	10165-10167	to	_
47-5	10168-10175	further	_
47-6	10176-10184	contrast	_
47-7	10185-10188	and	_
47-8	10189-10197	visually	_
47-9	10198-10205	display	_
47-10	10206-10214	patterns	_
47-11	10215-10217	of	_
47-12	10218-10225	percent	_
47-13	10226-10230	BOLD	_
47-14	10231-10238	signals	_
47-15	10239-10242	for	_
47-16	10243-10246	our	_
47-17	10247-10255	contrast	_
47-18	10256-10258	of	_
47-19	10259-10267	interest	_
47-20	10268-10270	in	_
47-21	10271-10274	our	_
47-22	10275-10278	key	_
47-23	10279-10291	hypothesized	_
47-24	10292-10295	OT-	_
47-25	10296-10299	and	_
47-26	10300-10313	DA-innervated	_
47-27	10314-10321	regions	_
47-28	10322-10323	.	_

48-1	10324-10326	In	_
48-2	10327-10330	all	_
48-3	10331-10339	analyses	_
48-4	10340-10341	,	_
48-5	10342-10353	statistical	_
48-6	10354-10363	threshold	_
48-7	10364-10366	of	_
48-8	10367-10372	false	_
48-9	10373-10382	discovery	_
48-10	10383-10387	rate	_
48-11	10388-10389	(	_
48-12	10390-10393	FDR	_
48-13	10394-10395	)	_
48-14	10396-10405	corrected	_
48-15	10406-10407	q	_
48-16	10408-10409	<	_
48-17	10410-10413	.05	_
48-18	10414-10417	and	_
48-19	10418-10419	a	_
48-20	10420-10427	cluster	_
48-21	10428-10437	threshold	_
48-22	10438-10440	of	_
48-23	10441-10442	≥	_
48-24	10443-10446	300	_
48-25	10447-10450	mm3	_
48-26	10451-10455	were	_
48-27	10456-10460	used	_
48-28	10461-10463	to	_
48-29	10464-10473	determine	_
48-30	10474-10482	clusters	_
48-31	10483-10485	of	_
48-32	10486-10497	significant	_
48-33	10498-10508	activation	_
48-34	10509-10510	.	_

49-1	10511-10526	Supra-threshold	_
49-2	10527-10535	clusters	_
49-3	10536-10538	of	_
49-4	10539-10545	active	_
49-5	10546-10552	voxels	_
49-6	10553-10557	were	_
49-7	10558-10565	labeled	_
49-8	10566-10571	using	_
49-9	10572-10573	a	_
49-10	10574-10583	published	_
49-11	10584-10589	atlas	_
49-12	10590-10592	of	_
49-13	10593-10596	the	_
49-14	10597-10602	human	_
49-15	10603-10608	brain	_
49-16	10609-10612	and	_
49-17	10613-10616	the	_
49-18	10617-10626	Talairach	_
49-19	10627-10633	Client	_
49-20	10634-10635	(	_
49-21	10636-10644	Research	_
49-22	10645-10652	Imaging	_
49-23	10653-10659	Center	_
49-24	10660-10661	,	_
49-25	10662-10664	TX	_
49-26	10665-10666	,	_
49-27	10667-10670	USA	_
49-28	10671-10672	)	_
49-29	10673-10674	.	_

50-1	10675-10684	Post-scan	_
50-2	10685-10692	ratings	_
50-3	10693-10701	analysis	_
50-4	10702-10711	Post-scan	_
50-5	10712-10719	ratings	_
50-6	10720-10724	were	_
50-7	10725-10733	analyzed	_
50-8	10734-10738	with	_
50-9	10739-10742	the	_
50-10	10743-10751	STATA/SE	_
50-11	10752-10753	,	_
50-12	10754-10761	version	_
50-13	10762-10766	13.1	_
50-14	10767-10774	XTMIXED	_
50-15	10775-10784	procedure	_
50-16	10785-10786	.	_

51-1	10787-10794	Mothers	_
51-2	10795-10796	’	_
51-3	10797-10804	ratings	_
51-4	10805-10807	of	_
51-5	10808-10814	affect	_
51-6	10815-10816	,	_
51-7	10817-10821	both	_
51-8	10822-10825	how	_
51-9	10826-10830	they	_
51-10	10831-10840	perceived	_
51-11	10841-10844	the	_
51-12	10845-10851	infant	_
51-13	10852-10854	to	_
51-14	10855-10857	be	_
51-15	10858-10865	feeling	_
51-16	10866-10868	in	_
51-17	10869-10873	each	_
51-18	10874-10879	image	_
51-19	10880-10883	and	_
51-20	10884-10886	of	_
51-21	10887-10892	their	_
51-22	10893-10896	own	_
51-23	10897-10906	affective	_
51-24	10907-10916	responses	_
51-25	10917-10919	to	_
51-26	10920-10923	the	_
51-27	10924-10929	image	_
51-28	10930-10931	,	_
51-29	10932-10936	were	_
51-30	10937-10945	compared	_
51-31	10946-10949	for	_
51-32	10950-10953	own	_
51-33	10954-10957	and	_
51-34	10958-10965	unknown	_
51-35	10966-10972	infant	_
51-36	10973-10978	faces	_
51-37	10979-10984	using	_
51-38	10985-10998	mixed-effects	_
51-39	10999-11005	linear	_
51-40	11006-11016	regression	_
51-41	11017-11025	analysis	_
51-42	11026-11030	that	_
51-43	11031-11039	included	_
51-44	11040-11041	a	_
51-45	11042-11055	subject-level	_
51-46	11056-11062	random	_
51-47	11063-11072	intercept	_
51-48	11073-11074	.	_

52-1	11075-11088	Mixed-effects	_
52-2	11089-11095	models	_
52-3	11096-11100	were	_
52-4	11101-11105	also	_
52-5	11106-11110	used	_
52-6	11111-11113	to	_
52-7	11114-11119	probe	_
52-8	11120-11123	for	_
52-9	11124-11127	the	_
52-10	11128-11139	association	_
52-11	11140-11147	between	_
52-12	11148-11155	mothers	_
52-13	11156-11157	’	_
52-14	11158-11161	two	_
52-15	11162-11169	ratings	_
52-16	11170-11172	to	_
52-17	11173-11180	examine	_
52-18	11181-11184	the	_
52-19	11185-11191	degree	_
52-20	11192-11194	to	_
52-21	11195-11200	which	_
52-22	11201-11208	mothers	_
52-23	11209-11210	’	_
52-24	11211-11214	own	_
52-25	11215-11224	affective	_
52-26	11225-11234	responses	_
52-27	11235-11242	tracked	_
52-28	11243-11247	with	_
52-29	11248-11251	how	_
52-30	11252-11256	they	_
52-31	11257-11266	perceived	_
52-32	11267-11270	the	_
52-33	11271-11277	infant	_
52-34	11278-11280	to	_
52-35	11281-11283	be	_
52-36	11284-11291	feeling	_
52-37	11292-11293	.	_

53-1	11294-11299	Model	_
53-2	11300-11308	building	_
53-3	11309-11312	was	_
53-4	11313-11320	carried	_
53-5	11321-11324	out	_
53-6	11325-11327	as	_
53-7	11328-11335	follows	_
53-8	11336-11337	:	_
53-9	11338-11339	(	_
53-10	11340-11341	a	_
53-11	11342-11343	)	_
53-12	11344-11347	the	_
53-13	11348-11355	initial	_
53-14	11356-11361	model	_
53-15	11362-11370	included	_
53-16	11371-11374	the	_
53-17	11375-11380	fixed	_
53-18	11381-11385	main	_
53-19	11386-11393	effects	_
53-20	11394-11396	of	_
53-21	11397-11403	infant	_
53-22	11404-11412	identity	_
53-23	11413-11414	(	_
53-24	11415-11419	i.e.	_
53-25	11420-11421	,	_
53-26	11422-11425	own	_
53-27	11426-11429	vs.	_
53-28	11430-11437	unknown	_
53-29	11438-11439	)	_
53-30	11440-11443	and	_
53-31	11444-11451	mothers	_
53-32	11452-11453	’	_
53-33	11454-11463	perceived	_
53-34	11464-11471	ratings	_
53-35	11472-11474	of	_
53-36	11475-11481	infant	_
53-37	11482-11483	’	_
53-38	11484-11485	s	_
53-39	11486-11492	affect	_
53-40	11493-11494	;	_
53-41	11495-11496	(	_
53-42	11497-11498	b	_
53-43	11499-11500	)	_
53-44	11501-11502	a	_
53-45	11503-11516	subject-level	_
53-46	11517-11523	random	_
53-47	11524-11533	intercept	_
53-48	11534-11537	was	_
53-49	11538-11543	added	_
53-50	11544-11546	to	_
53-51	11547-11552	model	_
53-52	11553-11563	systematic	_
53-53	11564-11580	inter-individual	_
53-54	11581-11592	variability	_
53-55	11593-11594	;	_
53-56	11595-11598	and	_
53-57	11599-11600	(	_
53-58	11601-11602	c	_
53-59	11603-11604	)	_
53-60	11605-11616	interaction	_
53-61	11617-11622	terms	_
53-62	11623-11627	were	_
53-63	11628-11633	added	_
53-64	11634-11646	sequentially	_
53-65	11647-11650	and	_
53-66	11651-11659	retained	_
53-67	11660-11662	in	_
53-68	11663-11666	the	_
53-69	11667-11672	model	_
53-70	11673-11675	if	_
53-71	11676-11680	they	_
53-72	11681-11689	improved	_
53-73	11690-11695	model	_
53-74	11696-11699	fit	_
53-75	11700-11701	.	_

54-1	11702-11705	The	_
54-2	11706-11712	models	_
54-3	11713-11717	were	_
54-4	11718-11724	fitted	_
54-5	11725-11727	by	_
54-6	11728-11735	maximum	_
54-7	11736-11746	likelihood	_
54-8	11747-11757	estimation	_
54-9	11758-11759	,	_
54-10	11760-11763	and	_
54-11	11764-11770	nested	_
54-12	11771-11777	models	_
54-13	11778-11782	were	_
54-14	11783-11793	contrasted	_
54-15	11794-11799	using	_
54-16	11800-11816	likelihood-ratio	_
54-17	11817-11828	chi-squares	_
54-18	11829-11830	.	_

